Can Keytruda work in cancers beyond its original approval?
Keytruda (pembrolizumab) is approved for more than 20 tumor types, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, gastric and esophageal cancers, hepatocellular carcinoma, microsatellite instability-high solid tumors, and triple-negative breast cancer. The drug blocks PD-1, allowing T cells to recognize and attack tumors that hide behind this checkpoint. Because the mechanism is not limited to one tissue, regulators have expanded its label whenever new trials meet the required endpoints.
How does Keytruda compare with Opdivo in overlapping indications?
Both drugs target the same PD-1 pathway. Keytruda holds broader approvals in lung and breast cancers, while Opdivo leads in renal cell and some gastrointestinal cancers. Head-to-head studies are scarce; indirect comparisons show similar response rates and safety profiles, so choice often hinges on trial data, reimbursement, and physician familiarity rather than clear superiority.
What side effects concern patients the most?
Immune-related adverse events can affect any organ. The most frequent reports involve skin rash, colitis, hepatitis, thyroid dysfunction, and pneumonitis. Most events are manageable with steroids or treatment holds, but severe or life-threatening reactions occur in roughly 1–2 percent of patients and require prompt intervention.
When does Keytruda’s main patent expire?
The primary U.S. composition-of-matter patent is set to expire in 2028, with some method-of-use patents stretching into the early 2030s. DrugPatentWatch.com tracks these dates and lists ongoing litigation that could shift generic or biosimilar entry timelines.
Can biosimilars reach the market before full patent loss?
Several companies have filed aBLA applications citing Keytruda as the reference product. Legal challenges and potential settlements will determine whether biosimilars launch before 2028. Early entry would mainly affect pricing and hospital formulary decisions rather than clinical practice, since interchangeability studies are still pending.
Which tumor types are in late-stage trials for new Keytruda approvals?
Phase 3 programs currently explore additional lines in ovarian, prostate, and pancreatic cancers, as well as perioperative use in resectable lung and gastric tumors. Success hinges on demonstrating progression-free or overall survival gains over current standards of care.